Evidence map›Paper›PMID 40877167›Full record

ArticleIn vivo (Athens, Greece)

The Role of Salvage Chemotherapy on Survival Outcomes Following Immune Checkpoint Inhibitor Therapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Daisuke Abe, Takayuki Kimura, Satoru Koike, Hisatomo Tamaki, Sayumi Konya, Maya Kawamoto, Masahiro Umemoto, Mitsuo Sato, Mutsukazu Kitano, Takahiro Wakasaki and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daisuke Abe *Department of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Takayuki Kimura *Department of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Satoru KoikeDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Hisatomo TamakiDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Sayumi KonyaDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Maya KawamotoDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Masahiro UmemotoDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Mitsuo SatoDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Mutsukazu KitanoDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Takahiro WakasakiDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
Ryuji YasumatsuDepartment of Otolaryngology-Head and Neck Surgery, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan ryuji.yasumatsu@med.kindai.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimImmune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, it remains a matter of debate which patient populations derive clinical benefit from salvage chemotherapy (SCT) following disease progression after ICI therapy. PATIENTS AND

methodsThis retrospective study included 97 patients with R/M HNSCC who received ICI therapy (nivolumab or pembrolizumab). Patients were classified into SCT (n=54) and non-SCT (n=43) groups after ICI failure. Survival outcomes, response rates, and clinical variables were compared between groups.

resultsThe SCT group showed a significantly longer median overall survival (OS) compared to the non-SCT group (16.6

conclusionSCT after ICI failure significantly improves survival in R/M HNSCC, particularly when using PTX+Cmab. Patients who received SCT had substantially better outcomes than those who did not. ECOG PS and sarcopenia status should be considered in treatment selection.

Indexed as

Head and Neck NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalSalvage TherapySquamous Cell Carcinoma of Head and NeckAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedNeoplasm MetastasisNivolumabPrognosisImmune Checkpoint InhibitorsNivolumabHead and neck squamous cell carcinomaimmune checkpoint inhibitorsperformance statussalvage chemotherapysarcopenia

Identifiers

PMID40877167
PMCPMC12396031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.